[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcoidosis-lung\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcoidosis-lung":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637681","a-comparison-of-a-medication-adherence-platform-fortiskap-vs-usual-care-in-subjects-on-oral-medications-for-the-treatment-of-interstitial-lung-disease-sarcoid-and-pulmonary-hypertension-100637681",false,"NCT07613216","A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension","Inclusion Criteria:\n\n1. 21 years of age or older at time of enrollment\n2. Primary diagnosis of interstitial lung disease (including sarcoidosis) AND\u002FOR pulmonary hypertension\n3. Currently managing their oral medications independently (i.e., without requiring caregiver administration)\n4. At least one oral medication with a primary indication for treatment of ILD or PH already in use, or planned for initiation with insurance approval secured, at the time of enrollment\n5. 6-Minute Walk Test (6MWT) scheduled within the next 30 days or performed within the past 30 days\n6. For ILD subjects: FVC and\u002For DLCO scheduled within the next 30 days or performed within the past 90 days\n7. For PH subjects: Cardiac echocardiography scheduled within the next 30 days or performed within the past 90 days\n8. Daily access to a smartphone compatible with the FORTISKAP™ companion application\n9. Proficient in English\n\nExclusion Criteria:\n\nFailure to meet any one of the above inclusion criteria","ALL","21 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.",[23,24,25,26],"Idiopathic Pulmonary Fibrosis (IPF)","Sarcoidosis Lung","Pulmonary Hypertension","Usual Interstitial Pneumonia",[28,29,30,31],"medication adherence","Interstitial Lung Disease","nintedanib","pirfenidone","NOT_YET_RECRUITING","2026-05-26",{"date":35,"type":36},"2026-05-29","ACTUAL",{"date":38,"type":19},"2026-07",{"date":40,"type":19},"2027-08",{"name":42,"class":43},"Cosmos Rx, Inc","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100581709","comparative-diagnostic-yield-of-endobronchial-cryo-biopsy-vs-forceps-biopsy-in-patients-with-suspected-sarcoidosis-100581709","NCT06853834","Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis","Prospective Randomized Controlled Study Comparing Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients Undergoing Endobronchial Ultrasound Guided Transbronchial Needle Aspiration for Suspected Sarcoidosis","CREBS","Inclusion Criteria:\n\nAll patients of suspected pulmonary sarcoidosis scheduled for routine EBUS-TBNA\n\nExclusion Criteria:\n\n1. Patient age less than 18 years\n2. Patients with co-morbid conditions like Diabetes mellitus, renal failure, chronic liver disease or any other chronic disease.\n3. Patients already on treatment with steroids or h\u002Fo steroids intake in last three months or on disease modifying and immunosuppressive drugs.\n4. Final Diagnosis other than sarcoidosis","18 Years",{"count":55,"type":19},150,"INTERVENTIONAL",[58],"NA","Sarcoidosis is a multi-systemic granulomatous disease of unknown cause that is characterized by the formation of non-caseous epithelioid cell granulomas. Sarcoidosis involves the respiratory system in \\> 90% of cases, usually the hilar and mediastinal nodes, and, less frequently, the lung tissue. Airway involvement, as judged by clinical features, physiologic testing, imaging techniques, bronchoscopy, and airway mucosal biopsy, has been observed in nearly two-thirds of patients with sarcoidosis. Although sarcoidosis involving thoracic lymph nodes and pulmonary parenchyma is familiar to most clinicians, airway involvement is often overlooked. The frequency of airway involvement increases as the parenchymal disease progresses, and\\\\airway involvement is associated with increased morbidity, respiratory symptoms, and mortality. The initial airway abnormality is the inflammation manifested by mucosal edema, erythema, and the formation of granulomas. As the airway disease progresses, the mucosa may demonstrate granularity, nodularity, cobble stoning, and friability. Sarcoid granulomas tend to develop along the bronchovascular bundle or in the vicinity of the airways. Overall quality of the endobronchial biopsy (EBB) will depend on the method by which it is obtained and cryo-EBB will most likely to provide better tissue for the diagnosis in comparison to forceps biopsy which has smaller sample as well as crush artifacts. Therefore, it is hypothesized that cryo-EBB will be better than forceps EBB and combined together it will increase the overall diagnostic yield of the sarcoidosis when combined with lymph node sampling by endobronchial ultrasound guided trans-bronchial needle aspiration (EBUS-TBNA).\n\n1. Primary objective: To compare the diagnostic yield of cryo-EBB with forceps biopsy in patients undergoing routine EBUS-TBNA for suspected sarcoidosis.\n2. Secondary Objective: To evaluate the overall diagnostic yield of combined endobronchial biopsy and EBUS-TBNA in patients undergoing routine EBUS-TBNA for suspected sarcoidosis.\n\nThe relevance and the expected outcome of the proposed study\n\n1. The study will provide insight to obtain an endobronchial biopsy either with cryo probe or forceps\n2. The study will also provide information regarding overall increase in diagnostic yield if any when the endobronchial biopsies are combined with EBUS-TBNA.",[24,61],"Pulmonary Sarcoidosis",[63,64,61,65],"Forceps Endobronchial Biopsy","Cryo-Endobronchial Biopsy","Diagnostic yield of endobronchial biopsy in sarcoidosis","RECRUITING","2025-02-28",{"date":69,"type":36},"2025-03-03",{"date":71,"type":36},"2024-01-01",{"date":73,"type":19},"2025-04-30",{"name":75,"class":76},"Sanjay Gandhi Postgraduate Institute of Medical Sciences","OTHER_GOV"]